10-K · March 12, 2026
MBX Biosciences, Inc.'s 10-K for the period ending December 31, 2025, reveals significant advances in their clinical-stage biopharmaceutical development, particularly with canvuparatide, imapextide, and MBX 4291,…
Earnings analysis · 10-Q
MBX earnings analysis
Filed May 7, 2026 · Our reading of the company's report
The latest report
MBX Biosciences, Inc. reported a net loss of $23.5 million for Q1 2026, slightly improving from a $23.9 million loss in Q1 2025. Operating expenses were $27.3 million, up from $26.5 million in the prior year, largely…
Read full summary
MBX Biosciences, Inc. reported a net loss of $23.5 million for Q1 2026, slightly improving from a $23.9 million loss in Q1 2025. Operating expenses were $27.3 million, up from $26.5 million in the prior year, largely driven by increased general and administrative expenses. The company continues to operate without revenue as it advances its clinical pipeline, emphasizing its reliance on existing cash reserves for future funding.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Narrowed Net Loss
Net loss decreased to $23.5 million for Q1 2026 from $23.9 million in Q1 2025.
-
Increased Cash Reserves
Cash, cash equivalents, and marketable securities reached $440.0 million as of March 31, 2026, up from $373.7 million at year-end 2025.
-
Interest Income Growth
Interest income increased to $3.7 million in Q1 2026, compared to $2.6 million in Q1 2025.
-
Investment in R&D Continued
R&D expenses decreased to $18.5 million in Q1 2026 from $22.4 million in Q1 2025.
-
Increased G&A Expenses
G&A expenses surged to $8.8 million in Q1 2026, up from $4.1 million in Q1 2025 due to headcount expansion.
-
Future Clinical Trials
Management plans to initiate a Phase 3 clinical trial for canvuparatide in Q3 2026.
What to watch
-
High Operating Expenses
Total operating expenses increased to $27.3 million in Q1 2026, compared to $26.5 million in the previous year.
-
Dependency on External Funding
The company has not generated any revenue from product sales and will rely on existing cash reserves and new funding.
-
Continued Clinical Trial Risks
Clinical trials may encounter delays or failures, impacting future funding and product development timelines.
Management's outlook
No explicit numeric guidance provided; company expects to continue funding operations until at least 2029 based on current cash reserves.
Earlier filings 4
10-Q · November 6, 2025
MBX Biosciences reported a net loss of $21.6 million for Q3 2025, an increase from a $18.1 million loss in the same period last year. Operating expenses rose to $23.9 million, driven largely by increased research and…
10-Q · August 7, 2025
MBX Biosciences reported a net loss of $19.4 million for Q2 2025, wider than the $15.9 million loss in Q2 2024, reflecting increased operational expenses driven by R&D initiatives. Notably, total operating expenses rose…
10-Q · May 12, 2025
MBX Biosciences reported a significant increase in net losses for Q1 2025, which totaled $23.9 million compared to $12.3 million in Q1 2024. Operating expenses surged to $26.5 million, more than doubling from the…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.